BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, January 2, 2026
See today's BioWorld
Home
» Sosei, Allergan pause Alzheimer's program to probe preclinical toxicity
To read the full story,
subscribe
or
sign in
.
Sosei, Allergan pause Alzheimer's program to probe preclinical toxicity
Sep. 19, 2018
By
Nuala Moran
LONDON – Another Alzheimer's disease program has run into problems, with Sosei Group Corp. and partner Allergan plc halting development of HTL-0018318 after cynomolgus monkeys in a toxicology study developed neoplastic tumors.
BioWorld
